Phase I trial of nivolumab in pediatric patients with malignant solid tumors or Hodgkin lymphoma
Latest Information Update: 03 Nov 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease; Solid tumours
- Focus Adverse reactions
- Acronyms PENGUIN
- 31 Oct 2022 Status changed from active, no longer recruiting to completed.
- 23 Mar 2021 Planned End Date changed from 31 Mar 2021 to 31 Mar 2022.
- 28 Jan 2021 According to an Ono Pharmaceutical media release, the company has submitted a supplemental application for Opdivo (generic name: nivolumab) Intravenous Infusion in Japan to expand the use for the treatment of pediatric patients with recurrent or refractory classical Hodgkin lymphoma for a partial change in approved items of the manufacturing and marketing approval, based on data from this trial.